Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

Elevated Intraocular Pressure Clinical Trial

— TC-002-301  

Official title:

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05165290
• Other study ID #: TC-002-301
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: November 29, 2021
• Est. completion date: September 2022

Study information

• Verified date: May 2022
• Source: TearClear Corp
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TearClear latanoprost Ophthalmic Solution, 0.005% (TC-002) compared to latanoprost Ophthalmic Solution, 0.005% (LAT) in subjects with elevated intraocular pressure at approximately 20 study sites located in the United States

Description:

This is a Phase 3, randomized, investigator-masked, multicenter, parallel-group trial comparing two ophthalmic solution formulations of latanoprost at a fixed dose of 0.005% administered once daily (QD) for 12 weeks.

Approximately 300 subjects will be randomized in this study at approximately 20 sites in the United States (US).

Treatment assignments will be masked to TearClear, study subjects, Investigators and site staff. Because the container closure for the investigational product is different, this study will use an unmasked dosing coordinator at each study site. All clinical trial supplies will be masked by using carton boxes to mask the appearance of the immediate container closure.

At approximately 2 select sites, approximately10% of total randomized subjects will have systemic PK labs drawn.

The study involves 7 clinic visits, including Screening (Visit 1), Randomization (Visit 2) and treatment visits (Visits 3, 5 and 7, during which ophthalmic assessments will occur and IOP will be assessed diurnally. There will be two interim IP dispensation visits (Visits 4 and 6).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 300
• Est. completion date: September 2022
• Est. primary completion date: September 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Greater than 18 years old.

2. Have been diagnosed and treated for bilateral open-angle glaucoma or ocular hypertension in both eyes.

3. Currently and for at least 30 days prior to screening, are being treated with a stable dose of latanoprost ophthalmic solution or prostaglandin analog for which there is a documented and positive treatment response with either agent maintained within both eyes.

4. Have best corrected visual acuity (BCVA) via Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) score +0.6 logarithm of the minimum angle of resolution (logMAR) or better in each eye.

5. At Visit 1, have IOP on prostaglandin or prostaglandin analog single therapy = 21mmHg, at Visit 2, have diurnal IOP between 22 and 30 mmHG, inclusive for each eye.

6. In the Investigator's judgment, are able to safely discontinue current ocular hypotensive medication during the washout period.

7. Willing and able to avoid wearing contact lenses from Visit 1 (Screening) and for the duration of the trial.

8. Willing and able to self-administer or have an able person available on a daily basis to assist with administration of study medication.

9. Female subjects must either be incapable of pregnancy because of bilateral oophorectomy, hysterectomy, or bilateral tubal ligation, or be post-menopausal (have been amenorrheic for at least 2 years) or must use an effective (e.g., double-barrier) method of birth control for the duration of the study. Female subjects of childbearing potential must have a negative pregnancy test and not be nursing.

10. Willing and able to comply with all study procedures.

Exclusion Criteria:

1. Causes of glaucoma other than primary open-angle glaucoma, including:

1. narrow angles (3 quadrants with less than Grade 2 according to Shaffer anterior chamber angle grading system) and subjects with angle closure

2. clinically significant peripheral anterior synechiae

3. congenital glaucoma

4. a history of angle closure in either eye

5. aphakic glaucoma

6. traumatic glaucoma

7. neovascular glaucoma

8. pigmentary glaucoma

9. pseudoexfoliative glaucoma

10. drug-induced glaucoma

2. Using a multi-drop treatment (other than prostaglandin or prostaglandin analog) for IOP-lowering medications.

3. Advanced glaucoma or subjects with a cup/disc ratio greater than 0.8.

4. Have undergone incisional IOP-lowering surgeries a placement or removal of minimally invasive glaucoma implant (MIG) in either eye.

5. Have undergone non-incisional IOP-lowering surgeries within the past 6 months.

6. Used anti-vascular endothelial growth factor (anti-VEGF) within 12 months of screening.

7. Used intraocular, periocular or topical corticosteroids within 60 days of screening.

8. Have received laser surgery for glaucoma (selective laser trabeculoplasty [SLT] or argon laser trabeculoplasty [ALT]) within 6 months of screening.

9. Have uveitis, iritis or congenital aphakia.

10. Are unwilling to discontinue current glaucoma medication within 30 days of the randomization (Visit 2).

11. Have had intraocular or periocular surgery within the past 3 months.

12. Are non-responsive to topical prostaglandins, prostamides or prostaglandin analogs in the Investigator's judgement.

13. History of previous complicated cataract surgery, or previous refractive keratotomy in either eye.

14. Used miotics and oral/topical carbonic anhydrase inhibitors within 5 days of screening.

15. Have any known hypersensitivity to any components of the formulation or latanoprost.

16. Have participated in a clinical trial for IOP-lowering investigational product or exposure to an IP within the prior 30 days.

17. In the judgement of the Investigator, have previous or currently active clinically significant systemic or ocular disease in either eye that could affect study outcome.

Related Conditions & MeSH terms

• Elevated Intraocular Pressure
• Ocular Hypertension

Intervention

Drug:
• Latanoprost ophthalmic solution, 0.005%
Commercially available, FDA-approved generic latanoprost ophthalmic solution, 0.005% (LAT) without modification will be used as the active control
• TC-002 latanoprost ophthalmic solution, 0.005%
TC-002 is formulated using the commercially available latanoprost drug substance; delivered drop to the eye is preservative-free.

Locations

Country	Name	City	State
United States	Abrams Eye Center	Cleveland	Ohio
United States	Scott & Christie Associates PC	Cranberry Township	Pennsylvania
United States	Segal Drug Trials	Delray Beach	Florida
United States	Louis M. Alpern, M.D., M.P.H., P.A.	El Paso	Texas
United States	Orange County Ophthalmology Medical Group	Garden Grove	California
United States	Global Research Management	Glendale	California
United States	Houston Eye Associates	Houston	Texas
United States	Shettle Eye Research Inc.	Largo	Florida
United States	The Eyecare Institute/Butcherton Clinical Trials	Louisville	Kentucky
United States	Total Eye Care P.A.	Memphis	Tennessee
United States	North Valley Eye Medical Group	Mission Hills	California
United States	Eye Research Foundation	Newport Beach	California
United States	North Bay Eye Associates	Petaluma	California
United States	Martel Eye Medical Group	Rancho Cordova	California
United States	Rochester Ophthalmological Group PA	Rochester	New York
United States	R&R Research LLC	San Antonio	Texas
United States	San Antonio Eye Center	San Antonio	Texas
United States	International Research Center	Tampa	Florida
United States	Wolstan & Goldberg Eye Associates	Torrance	California
United States	Michael K. Tran, MD	Westminster	California

Sponsors (1)

Lead Sponsor	Collaborator
TearClear Corp

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary efficacy endpoint is the difference in mean change from baseline (CFB) in IOP		Weeks 2, 6, and 12 at 8:00 AM, 10:00 AM, and 4:00 PM.
Secondary	Secondary efficacy endpoints include diurnal (average of 8:00 AM, 10:00 AM, and 4:00 PM measurements) IOP		Weeks 2, 6, and 12.